Michelle Sexton

Title(s)Assistant Adjunct Professor, Anesthesiology
SchoolHealth Sciences
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Bastyr University, Seattle, WAND06/2008Naturopathic Medicine
    University of Washington, Seattle, WApostdoctoral fellowship09/2011cannabinoid pharmacology

    Collapse Overview 
    Collapse Overview
    Dr. Sexton received her Doctor of Naturopathy degree from Bastyr University and followed this with an individual Postdoctoral Fellowship at University of Washington in the Department of Pharmacology. At UCSD, Dr. Sexton is involved in education and development of research in the field of medical cannabis.

    Dr. Sexton's clinical research focuses on the role of the endocannabinoid system in health and disease. She is an active investigator in several ongoing research projects researching medical cannabis in neuropathic pain, migraine, opioids tapering and effects across many disease states.

    Collapse Research 
    Collapse Research Activities and Funding
    Medical Cannabis Use in Patients with Chronic Pain
    Sep 1, 2018 - Aug 31, 2019
    Role: PI
    Role Description: The purpose of this study is to retrospectively review the medical charts of Pain Clinic patients receiving chronic opioids. We will compare patients with various pain diagnoses who did/did not receive a medical cannabis recommendations as an adjuvant to the opioids. From the medical chart we will record whether there were changes in pain and relief scores over time, changes in anxiety or depression over time and whether patients tapered down on their opiates or other associated medications (such as anxiolytics or antidepressants and sleep medications). We will use a morphine milligram equivalent conversion to standardize the ability to quantify opiates medications. We plan to conduct a follow-up telephone interview with the patients who did receive a recommendation for medical cannabis to determine how many patients continue to use medical cannabis, methods of administration (inhaled, oral) and any information on the potency of the products they are using (mg doses of THC and/or CBD and % THC/CBD potency of flower material).
    Cannabidiol in Pain Symptom Management
    Albert Einstein School of Medicine Aug 1, 2018
    Role: Co-Investigator
    Role Description: The goal of this study is to gather information thatwe hope will provide health care providers withmore knowledge about how and when to recommend patients use Cannabidiol (CBD). Cannabidiol (CBD) is being used with increased frequency by medical cannabis patients across the country. CBD is felt to have many possible therapeutic benefits, but there is very little data inthe medical literature from controlled clinical trials that allows health care providers to know how to advise people on how to use CBD and for what conditions and symptoms it may work best.

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Corroon J, Sexton M, Bradley R. Indications and administration practices amongst medical cannabis healthcare providers: a cross-sectional survey. BMC Fam Pract. 2019 12 14; 20(1):174. PMID: 31837706.
      View in: PubMed
    2. Sexton M, Cuttler C, Mischley LK. A Survey of Cannabis Acute Effects and Withdrawal Symptoms: Differential Responses Across User Types and Age. J Altern Complement Med. 2019 Mar; 25(3):326-335. PMID: 30383388.
      View in: PubMed
    3. Sexton M, Shelton K, Haley P, West M. Erratum: Evaluation of Cannabinoid and Terpenoid Content: Cannabis Flower Compared to Supercritical CO2 Concentrate. Planta Med. 2018 03; 84(4):E3. PMID: 29165726.
      View in: PubMed
    4. Sexton M, Shelton K, Haley P, West M. Evaluation of Cannabinoid and Terpenoid Content: Cannabis Flower Compared to Supercritical CO2 Concentrate. Planta Med. 2018 Mar; 84(4):234-241. PMID: 28926863.
      View in: PubMed
    5. Corroon JM, Mischley LK, Sexton M. Cannabis as a substitute for prescription drugs - a cross-sectional study. J Pain Res. 2017; 10:989-998. PMID: 28496355.
      View in: PubMed
    6. Cuttler C, Mischley LK, Sexton M. Sex Differences in Cannabis Use and Effects: A Cross-Sectional Survey of Cannabis Users. Cannabis Cannabinoid Res. 2016; 1(1):166-175. PMID: 28861492.
      View in: PubMed
    7. Sexton M, Cuttler C, Finnell JS, Mischley LK. A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy. Cannabis Cannabinoid Res. 2016; 1(1):131-138. PMID: 28861489.
      View in: PubMed
    8. Sexton M, Cudaback E, Abdullah RA, Finnell J, Mischley LK, Rozga M, Lichtman AH, Stella N. Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. Inflammopharmacology. 2014 Oct; 22(5):295-303. PMID: 25135301.
      View in: PubMed
    9. Sexton M, Silvestroni A, Möller T, Stella N. Differential migratory properties of monocytes isolated from human subjects naïve and non-naïve to Cannabis. Inflammopharmacology. 2013 Jun; 21(3):253-9. PMID: 22492174.
      View in: PubMed
    10. Sexton M, Woodruff G, Horne EA, Lin YH, Muccioli GG, Bai M, Stern E, Bornhop DJ, Stella N. NIR-mbc94, a fluorescent ligand that binds to endogenous CB(2) receptors and is amenable to high-throughput screening. Chem Biol. 2011 May 27; 18(5):563-8. PMID: 21609837.
      View in: PubMed
    11. Sexton M, Woodruff G, Cudaback E, Kreitzer FR, Xu C, Lin YH, Möller T, Bai M, Manning HC, Bornhop D, Stella N. Binding of NIR-conPK and NIR-6T to astrocytomas and microglial cells: evidence for a protein related to TSPO. PLoS One. 2009 Dec 18; 4(12):e8271. PMID: 20020060.
      View in: PubMed
    12. Bai M, Sexton M, Stella N, Bornhop DJ. MBC94, a conjugable ligand for cannabinoid CB 2 receptor imaging. Bioconjug Chem. 2008 May; 19(5):988-92. PMID: 18444670.
      View in: PubMed
    13. Manning HC, Smith SM, Sexton M, Haviland S, Bai M, Cederquist K, Stella N, Bornhop DJ. A peripheral benzodiazepine receptor targeted agent for in vitro imaging and screening. Bioconjug Chem. 2006 May-Jun; 17(3):735-40. PMID: 16704212.
      View in: PubMed